A modified chronic ocular hypertension rat model for retinal ganglion cell neuroprotection

Neuroprotective role of epigallocatechin-3-gallate in acute glaucoma via the nuclear factor-κB signalling pathway

Glaucoma is a disease involving impaired visual function accompanied by degeneration and necrosis of the optic nerve. Epigallocatechin-3-gallate (EGCG) exerts a neuroprotective effect against the degeneration of retinal ganglion cells. However, whether EGCG can relieve glaucoma and the possible mechanisms remain unclear. In order to determine the function of EGCG in glaucoma, an acute glaucoma rat model was established. Optic neuropathology was examined by haematoxylin-eosin staining and immunofluorescence staining for class III-β tubulin. The levels of inflammation-associated cytokines, such as interleukin (IL)-4, IL-6, TNF-α, IL-1β, IL-13 and IFN-γ were measured by flow cytometry. T cell proliferation was assessed by the carboxyfluorescein diacetate succinimidyl ester method. Finally, the functional role of EGCG in glaucoma was explored. The levels of the inflammation-associated proteins p-IκBα and p-p65 were measured by western blot analysis. The results showed that optic nerve injury occurred, and elevated levels of the inflammatory cytokines IL-4, IL-6, TNF-α, IL-1β, IL-13 and IFN-γ were observed in the rat model of acute glaucoma. In addition, an increased T lymphocyte proliferation rate and imbalance of Th1/Th2 cytokines were present in the models. Importantly, treatment with EGCG significantly alleviated optic nerve injury. At the molecular level, EGCG decreased the levels of inflammation-associated cytokines, decreased the proliferation rate of T lymphocyte cells, and repaired the imbalance of Th1/Th2 cytokines. Moreover, EGCG inhibited the increase in the phosphorylation of IκBα and p65 caused by modelling and thus suppressed the activation of the nuclear factor (NF)-κB signalling pathway. The findings of the present study indicate that EGCG could attenuate the symptoms of glaucoma and inhibit inflammatory responses by suppressing the NF-κB signalling pathway in a rat glaucoma model.

Establishment of an experimental glaucoma animal model: A comparison of microbead injection with or without hydroxypropyl methylcellulose

The present study aimed to compare microbead injection with and without hydroxypropyl methylcellulose (HPM) in order to establish an experimental animal model of glaucoma. This model was established in C57BL/6 mice and transgenic mice expressing cyan fluorescent protein (CFP) under the control of the Thy1 promoter in retinal ganglion cells (RGCs). C57BL/6 mice aged between 12 and 20 weeks old were randomly separated into three groups, which received different injections into the anterior chamber of the eye. Group A (microbead) received 2 µl microbeads (10×106 beads/ml) and 1 µl air. Group B (microbeads + HPM) received 2 µl microbeads and 1 µl HPM. Group C (control group) received 2 µl PBS and 1 µl air. The intraocular pressure (IOP) was measured with a tonometer under topical anesthesia daily for 1 month. A single injection of microbeads, with or without HPM, induced consistent IOP elevation when compared with the control group. Thy1-CFP mice received an injection of 2 µl microbeads and 1 µl HPM into the anterior chamber of the eyes, and the number of CFP+ RGCs was subsequently assessed in vivo by confocal scanning laser microscopy in the same area of the retina weekly for 6 weeks. The results from in vivo imaging of Thy1-CFP mice were comparable with the immunohistochemical staining results from the C57BL/6 mice. The combined injection of microbeads and HPM induced longer and higher peaks of IOP elevation when compared with the microbeads alone. The rate of RGC loss following the administration of microbeads alone was 25.0±1.3% 6 weeks after the initial IOP elevation, while it was 33.2±1.9% following the administration of microbeads + HPM. These results indicate that the injection of microbeads + HPM is a more effective method of establishing a mouse model with chronic elevation of IOP. In addition, the in vivo imaging that can be used with this technique provides an effective and noninvasive approach for monitoring the progress of RGC loss.

[Complement activation after induction of ocular hypertension in an animal model]

BACKGROUND

Although an elevated intraocular pressure (IOP) is known as the main risk factor for glaucoma, many studies also showed an involvement of the immune system in this disease. In this study we investigated if a moderate increase in IOP leads to activation of the complement system.

METHODS

The IOP was elevated experimentally in the left eye of rats, whereas the fellow eye served as the control. The IOP was measured at regular intervals. The number of retinal ganglion cells (RGC) was quantified via NeuN staining. To evaluate the activation of the complement system staining for C3, membrane attack complex (MAC), and mannose-binding lectin (MBL) was performed. Furthermore, we investigated possible glia activation (GFAP and vimentin) and apoptosis (Bax).

RESULTS

A moderate elevation of the IOP was noted from day 11 after induction of ocular hypertension (OHT) until the end of the study (28 days, p = 0.0005). In the OHT-group significantly fewer RGCs (p = 0.02) were detected. Additionally, we noted significant C3 and MAC activation in the ganglion cell layer (C3, p = 0.001 and MAC, p = 0.02) as well as in the total retina (C3, p = 0.002 and MAC, p = 0.012). An activation via the lectin pathway by MBL staining could not be detected (p = 0.40). At this point in time no alterations with regard to glia cells were noted (GFAP, p = 0.97 and vimentin, p = 0.99). No apoptosis via Bax pathway could be observed (p = 0.90).

CONCLUSION

The results suggest that the complement system is involved in the loss of RGCs even by a moderate IOP elevation which was indicated by significantly more C3 and MAC depositions in the OHT group.